Shares of Zoetis have been roughly average performers over the past decade. The shares seem appealingly valued at recent ...

Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 ...

The reality is that people and animals will always need medicine, treatments, and other products to live long and comfortable ...

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and ...

In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Zoetis, with a price target of $215.00. The company’s shares closed last Friday at $147.35. Take advantage of ...

Animal health company Zoetis (NYSE:ZTS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.2% ...

Meanwhile, the company has an impeccable dividend program. The company has increased its payouts by 502% over the past decade ...

The global Veterinary Infectious Disease Diagnostics Market, valued at US$2.66 billion in 2024, stood at US$2.87 billion in ...

Zoetis Inc. Q2 2025 earnings highlight 8% organic revenue growth, raised guidance, and strong performance from Simparica and Key Dermatology franchises.

Zoetis (ZTS) stock surges premarket as the company posts strong Q2 2025 results and raises full-year outlook. Read more here.

Zoetis beats Q2 estimates with strong pet product sales and raises full-year guidance despite livestock sales decline and Librela weakness.

The company raised its full-year 2025 guidance, now expecting revenue between $9.45 billion and $9.6 billion, representing ...